Baton Rouge, LA – A Vascular Specialty Center physician has recently co-authored results of a Phase 3 multiple site, randomized, double-blind, controlled trial designed to evaluate the comparative efficacy and safety of rhThrombin and bovine thrombin in patients undergoing spinal surgery, hepatic resection, peripheral arterial bypass surgery, or arteriovenous graft formation for hemodialysis access (Journal of the American College of Surgeons 2007 Aug; 205(2):256-65.).  Results of this trial suggest that rhThrombin has comparable efficacy, a similar safety profile, and is considerably less immunogenic than bovine thrombin when used for surgical hemostasis.

“As a principle investigator and leading enroller for the trial, our efforts in the execution of this trial were vital to the success of this important research”, says Wendy Frierberger, director of clinical research, Vascular Specialty Center.